1. Unmet Needs in Schizophrenia

2. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Background on Schizophrenia

4. Timeline of FDA-Approved Antipsychotics

5. Comparison of Mechanisms of Action of Current Antipsychotic Agents

6. Current Antipsychotic Agents What They Can and Cannot Do

7. Side Effects of Atypical Antipsychotics Shift in Risk Perception

8. Current Antipsychotic Agents What They Can and Cannot Do

9. Treatment Effectiveness

10. Comparative Effectiveness of Current Antipsychotic Agents

11. What Are Continuing Unmet Needs in Schizophrenia Treatment?

12. Targets for Novel Drug Development

13. Summary of Newly Approved and Emerging Antipsychotic Agents

14. Binding Affinities of Cariprazine for Human Receptors In Vitro and Long-Term Effects on Functioning in Schizophrenia

15. Binding Affinities of Brexpiprazole for Human Receptors In Vitro and Long-Term Effects on Functioning in Schizophrenia

16. What Are Continuing Unmet Needs in Schizophrenia Treatment?

17. Binding Affinities of MIN-101 and Effects on Functioning in Schizophrenia

18. Evaluating Pimavanserin

19. Binding Affinities of RP5063 and Effects on Symptoms in Schizophrenia and Schizoaffective Disorder

20. Binding Affinities and Characteristics of Lumateperone (ITI-007)

21. Lumateperone Demonstrates Efficacy on PANSS Total Score and Improves Positive Symptoms

22. Safety Overview Lumateperone

23. What Are Continuing Unmet Needs in Schizophrenia Treatment?

24. Summary Points

25. Abbreviations

26. Abbreviations (cont)